Sorrento Enters Into Binding Term Sheet to Acquire Exclusive Rights to Abivertinib with Completed Registrational Trial Data in Non-Small Cell Lung Cancer Novel TKI compound with dual selective targeting of mutant forms of EGFR and BTKMore than 600 patients have been treated with the compound across studies, with over 200 patients in the completed...

Continued ICP Orders From Japanese Customers NEW HAVEN, Conn., March 05, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it continues to receive both new and repeat business from...

Precipio ICE COLD-PCR™ Technology Selected by the University of Cincinnati Medical Center for Liquid Biopsy Study NEW HAVEN, Conn., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced that its ICE COLD-PCR™ (ICP) technology has been selected for a...

Precipio Expands ICE-COLD PCR™ Lung Cancer Mutation Detection Offering New kit examines most relevant EGFR exons that impact therapeutic decisions for lung cancer patients NEW HAVEN, Conn., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Precipio, Inc. (NASDAQ: PRPO), announced...

Precipio Launches Unique Lung Cancer Monitoring Test for Therapy Resistance NEW HAVEN, Conn., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Precipio, Inc. (NASDAQ:PRPO) announced today its launch of the first lung cancer treatment resistance panel specifically for the critical...